Andros Pharmaceuticals Co.,Ltd vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Andros Pharmaceuticals Co.,Ltd (6917) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 14, 2026.
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Vertex Pharmaceuticals leads: 2 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Andros Pharmaceuticals Co.,Ltd
1 of 1 models see the stock below the current price.
Vertex Pharmaceuticals
21 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Andros Pharmaceuticals Co.,Ltd · Healthcare
Vertex Pharmaceuticals · Health Care
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Andros Pharmaceuticals Co.,Ltd trades at TWD 32.05 versus a fair value of TWD 5.23 (-84%), while Vertex Pharmaceuticals trades at $516 versus $279 (-46%).
Vertex Pharmaceuticals has the higher quality score (79/100).
See the full analysis →More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Related to Andros Pharmaceuticals Co.,Ltd
Alphabet Inc Class C vs Verizon CommunicationsAlphabet Inc Class C vs At&tAlphabet Inc Class C vs NetEaseAmazon.com vs Toyota Motor CorporationSee the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.